Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950723 | 0.85 | CA5A (0.56) | CA5ALMNAMAPTHPGDRAB9A | |
| SCHEMBL27617295 | 0.84 | CA5A (0.38) | CA5ALMNAMAPTHPGDRAB9A | |
| SCHEMBL17256645 | 0.84 | CES2 (0.39) | CA5ALMNAMAPTRAB9ANPC1 | |
| SCHEMBL3335983 | 0.82 | KMT2A (0.48) | CA5ALMNAMAPTHPGDRAB9A | |
| SCHEMBL2879040 | 0.80 | MAPT (0.38) | CA5AMAPTRAB9AKMT2ANPC1 | |
| SCHEMBL8319196 | 0.80 | LMNA (0.42) | LMNAMAPTHPGDRAB9AL3MBTL1 | |
| SCHEMBL20526141 | 0.79 | CES2 (0.45) | CA5AKMT2A | |
| SCHEMBL669554 | 0.78 | CA5A (0.67) | CA5ALMNAMAPTHPGDRAB9A | |
| SCHEMBL398487 | 0.74 | TSHR (0.45) | CA5ALMNAMAPTHPGDL3MBTL1 | |
| Acetonitrile SCHEMBL17477300 | 0.72 | CA5A (0.52) | CA5ALMNAMAPTHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| EP-2239057-B1 | Asymmetric catalyst and process for preparing optically active alcohols using the same | KANTO KAGAKU (JP) | 2015-06-03 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-8232420-B2 | Asymmetric catalyst and process for preparing optically active alcohols using the same | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100261924-A1 | ASYMMETRIC CATALYST AND PROCESS FOR PREPARING OPTICALLY ACTIVE ALCOHOLS USING THE SAME | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2239057-A1 | Asymmetric catalyst and process for preparing optically active alcohols using the same | Kanto Kagaku Kabushiki Kaisha (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| CN-1029405-C | Lipid A analogs having immunoactivating and anti-tumor activity | SANKYO CO (JP) | 1995-08-02 | — | — | CN | disclosed |
| WO-1995019767-A1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1995-07-27 | — | — | WO | disclosed |
| CN-1091432-A | Can suppress the active peptide of hiv protease, its preparation with and medical use | SANKYO CO (JP) | 1994-08-31 | — | — | CN | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| CN-1064683-A | New beta-amino-alpha-hydroxycarboxylic acids and uses thereof | SANKYO CO (JP) | 1992-09-23 | — | — | CN | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1052481-A | Lipoid category-A with immunocompetence and anti-tumor activity is like thing | SANKYO CO (JP) | 1991-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | CA5A 1939/4885LMNA 3744/4885MAPT 2855/4885 |
| US-20100261924-A1 | ASYMMETRIC CATALYST AND PROCESS FOR PREPARING OPTICALLY ACTIVE ALCOHOLS USING THE SAME | ADH1A, ADH1C, ADH5 | CA5A 2012/4885LMNA 2545/4885MAPT 4229/4885 |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | CA5A 280/4885LMNA 4251/4885MAPT 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.